These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 36621246)
1. Effectiveness of the BNT162b2 mRNA Covid-19 vaccine in Spanish healthcare workers. Núñez López C; González de Abreu JM; Pérez-Blanco V; de Miguel Buckley R; Romero Gómez MP; Díaz-Menéndez M; ; Enferm Infecc Microbiol Clin (Engl Ed); 2023 Jan; 41(1):33-35. PubMed ID: 36621246 [TBL] [Abstract][Full Text] [Related]
2. Effectiveness of the BNT162b2 mRNA Covid-19 vaccine in Spanish healthcare workers. Núñez López C; González de Abreu JM; Pérez-Blanco V; de Miguel Buckley R; Romero Gómez MP; Díaz-Menéndez M; ; Enferm Infecc Microbiol Clin (Engl Ed); 2021 Jul; ():. PubMed ID: 34391596 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness of the BNT162b2 mRNA Covid-19 vaccine in Spanish healthcare workers. Núñez López C; González de Abreu JM; Pérez-Blanco V; de Miguel Buckley R; Romero Gómez MP; Díaz-Menéndez M; ; Enferm Infecc Microbiol Clin; 2023 Jan; 41(1):33-35. PubMed ID: 34334860 [TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 new infections among health-care workers after the first dose of the BNT162b2 mRNA COVID-19 vaccine. A hospital-wide cohort study. Guijarro C; Galán I; Martínez-Ponce D; Pérez-Fernández E; Goyanes MJ; Castilla V; Velasco M Clin Microbiol Infect; 2021 Nov; 27(11):1699.e1-1699.e4. PubMed ID: 34197936 [TBL] [Abstract][Full Text] [Related]
5. Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers. Angel Y; Spitzer A; Henig O; Saiag E; Sprecher E; Padova H; Ben-Ami R JAMA; 2021 Jun; 325(24):2457-2465. PubMed ID: 33956048 [TBL] [Abstract][Full Text] [Related]
6. Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workers. Brunner WM; Freilich D; Victory J; Krupa N; Scribani MB; Jenkins P; Lasher EG; Fink A; Shah A; Cross P; Bush V; Peek LJ; Pestano GA; Gadomski AM Int J Infect Dis; 2022 Oct; 123():183-191. PubMed ID: 36044963 [TBL] [Abstract][Full Text] [Related]
7. Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up. Ponticelli D; Madotto F; Conti S; Antonazzo IC; Vitale A; Della Ragione G; Romano ML; Borrelli M; Schiavone B; Polosa R; Ferrara P; Mantovani LG Intern Emerg Med; 2022 Mar; 17(2):481-486. PubMed ID: 34637084 [TBL] [Abstract][Full Text] [Related]
8. Comparison of three dosing intervals for the primary vaccination of the SARS-CoV-2 mRNA Vaccine (BNT162b2) on magnitude, neutralization capacity and durability of the humoral immune response in health care workers: A prospective cohort study. Leong DP; Zhang A; Breznik JA; Clare R; Huynh A; Mushtaha M; Rangarajan S; Stacey H; Kim PY; Loeb M; Denburg JA; Mertz D; Chagla Z; Nazy I; Miller MS; Bowdish DME; Duong M PLoS One; 2023; 18(2):e0281673. PubMed ID: 36791069 [TBL] [Abstract][Full Text] [Related]
9. IgG anti-spike antibody levels in healthcare workers with and without prior COVID-19 up to 3 months after BNT162b2 vaccination. Van Elslande J; Weemaes M; Godderis L; Van Pottelbergh G; Bossuyt X; Vermeersch P Diagn Microbiol Infect Dis; 2022 Apr; 102(4):115638. PubMed ID: 35104720 [TBL] [Abstract][Full Text] [Related]
10. Effectiveness of BNT162b2 mRNA Coronavirus Disease 2019 (COVID-19) Vaccine Against Acquisition of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Among Healthcare Workers in Long-Term Care Facilities: A Prospective Cohort Study. Muhsen K; Maimon N; Mizrahi A; Bodenheimer O; Cohen D; Maimon M; Grotto I; Dagan R Clin Infect Dis; 2022 Aug; 75(1):e755-e763. PubMed ID: 34698808 [TBL] [Abstract][Full Text] [Related]
11. Prevalence of neutralizing antibodies against SARS-CoV-2 using a rapid serological test in health workers of a Spanish Department of Health in Alicante (Spain) before the booster dose of the vaccine. Montagud AC; Llenas-García J; Moragues R; Pérez-Bernabeu A; Alcocer Pertegal MJ; García Gómez FJ; Gamayo Serna AM; García Morante H; Caballero P; Tuells J Rev Clin Esp (Barc); 2024 Apr; 224(4):197-203. PubMed ID: 38423384 [TBL] [Abstract][Full Text] [Related]
12. [COVID-19 infections and effectiveness of the vaccination among healthcare workers]. Rojkovich B; Németh D; Dinya E; Nagy E; Török E; Lázár I; Perduk A; Géher P; Nagy G Orv Hetil; 2023 Feb; 164(5):163-171. PubMed ID: 36739547 [TBL] [Abstract][Full Text] [Related]
13. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study. Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD; Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524 [TBL] [Abstract][Full Text] [Related]
14. Immune response to one dose of BNT162b2 mRNA Covid-19 vaccine followed by SARS-CoV-2 infection: An Italian prospective observational study. Stefanizzi P; Larocca AMV; Martinelli A; Soldano S; Dell'Aera M; Migliore G; Germinario CA; Vimercati L; Tafuri S; Bianchi FP Vaccine; 2022 Mar; 40(12):1805-1809. PubMed ID: 35190212 [TBL] [Abstract][Full Text] [Related]
16. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine. Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR Front Immunol; 2022; 13():827306. PubMed ID: 35173736 [TBL] [Abstract][Full Text] [Related]
17. Depressive symptoms predict antibody titers after a second dose of the SARS-CoV-2 BNT162b2 vaccine among hospital workers in Japan. Kaneko H; Tsuboi H Brain Behav Immun; 2023 Jan; 107():414-418. PubMed ID: 36116693 [TBL] [Abstract][Full Text] [Related]
18. Antibody response induced by the BNT162b2 mRNA COVID-19 vaccine in a cohort of health-care workers, with or without prior SARS-CoV-2 infection: a prospective study. Buonfrate D; Piubelli C; Gobbi F; Martini D; Bertoli G; Ursini T; Moro L; Ronzoni N; Angheben A; Rodari P; Cardellino C; Tamarozzi F; Tais S; Rizzi E; Degani M; Deiana M; Prato M; Silva R; Bisoffi Z Clin Microbiol Infect; 2021 Dec; 27(12):1845-1850. PubMed ID: 34329793 [TBL] [Abstract][Full Text] [Related]
19. Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel. Spitzer A; Angel Y; Marudi O; Zeltser D; Saiag E; Goldshmidt H; Goldiner I; Stark M; Halutz O; Gamzu R; Slobodkin M; Amrami N; Feigin E; Elbaz M; Furman M; Bronstein Y; Chikly A; Eshkol A; Furer V; Mayer T; Meijer S; Melloul A; Mizrahi M; Yakubovsky M; Rosenberg D; Safir A; Spitzer L; Taleb E; Elkayam O; Silberman A; Eviatar T; Elalouf O; Levinson T; Pozyuchenko K; Itzhaki-Alfia A; Sprecher E; Ben-Ami R; Henig O JAMA; 2022 Jan; 327(4):341-349. PubMed ID: 35006256 [TBL] [Abstract][Full Text] [Related]
20. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study. Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]